Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 19Thoracic 1Other neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 630Triple Negative Breast Neoplasms 166Ovarian Neoplasms 103Carcinoma, Non-Small-Cell Lung 100Neoplasm Metastasis 76Colorectal Neoplasms 64Melanoma 61Stomach Neoplasms 60Neoplasms 56Pancreatic Neoplasms 55Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 48Endometrial Neoplasms 48Lung Neoplasms 47Uterine Cervical Neoplasms 36Carcinoma, Renal Cell 35Sarcoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Breast Neoplasms, Male 29Urinary Bladder Neoplasms 26Small Cell Lung Carcinoma 26Colonic Neoplasms 26Carcinoma, Transitional Cell 23Carcinoma, Ovarian Epithelial 21Lymphoma 18Brain Neoplasms 18Kidney Neoplasms 17Carcinoma, Hepatocellular 17Liver Neoplasms 15

Interventions

zanidatamab 1trastuzumab deruxtecan 1Trastuzumab 1Capecitabine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma Of Esophagus × Breast × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡